AlphAIAlphAI — Financial news for AI agents
scanx.tradeSEP 212 min read$ANAB

AnaptysBio Q2FY26 Results: Adj. EPS beats est, sales up 23%

AnaptysBio (ANAB) reported Q2FY26 adjusted EPS of $(0.11), beating estimates by 76%. Revenue rose 23% YoY to $27.5M, exceeding expectations. Net income surged to $177.3M due to a $181.5M tax benefit. Jemperli sales grew 34% YoY to $644M. Cash position declined to $164.1M.

Original reporting
scanx.trade
Published Sep 21, 2026, 8:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 9:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AnaptysBio Q2FY26 Results: Adj. EPS beats est, sales up 23% — source image
Source · scanx.trade
Decision brief

The 30-second read

$ANABBullishHigh
01

Why it matters

Earnings beat may trigger short-term buying, but investors should assess sustainability of cash flow.

02

Market read

First earnings release for the quarter; provides new data for valuation models.

03

What to watch

Litigation costs and royalty decline could pressure future margins.

Relevance 8/10Novelty 8/10Timing: post-market release

Background

AnaptysBio separated from First Tracks Biotherapeutics, impacting its tax position and cash balance.

Company-level read

Ticker impact

$ANABBullishHigh confidence
Context

AnaptysBio reported Q2FY26 adjusted EPS beat and a 23% sales increase, providing fresh earnings data.

Expected impact

Potential modest price rise on earnings beat, but watch for volatility due to tax benefit normalization.

Evidence & confidence

Adjusted EPS beat and revenue growth are positive, but the net income is largely accounting-driven, limiting upside.

Market effects

Sector

Biotech earnings may influence peer valuations, especially companies with royalty streams.

Regional

Limited to US biotech sector.

Global

Modest, confined to specialty pharma investors.

Counterpoint

What could challenge this read

Tax benefit is non-recurring; core cash generation remains weak, suggesting caution.

Key entities

  • company
    AnaptysBio

    Biotech firm reporting Q2FY26 results.

  • company
    GSK

    Partner in Jemperli royalties and litigation.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 25
$ANABHigh

How Return To Profit Will Impact AnaptysBio (ANAB) Investors

AnaptysBio (ANAB) reported Q4 2026 net income of $183.88M, reversing a year-earlier loss. Basic and diluted EPS were $6.06 and $4.93, respectively, with six-month net income at $131M. The shift to profitability raises questions about sustainability and market reaction, as the stock has risen over a year but fallen recently.

simplywall.st2 min
SEP 22
$DGXMed

Premarket movers: Quest, Labcorp hit by CMS cuts

U.S. stock index futures steadied on Tuesday. Quest Diagnostics (DGX) fell 6.9% and Labcorp (LH) dropped 4.5% after CMS proposed cuts to lab reimbursements. On Holding (ONON) rose 6.4% on a $1B share buyback plan. Vicor (VICR) surged 9.9% after raising Q3 revenue outlook. Endava (DAVA) fell 12% due to CFO investigation. GameStop (GME) gained 3.5% after CEO bought shares. AnaptysBio (ANAB) rose 3.8% on better-than-expected revenue.

investing.com2 min